Portfolio News
Sofinnova Crossover & Sofinnova Capital
Mainstay Medical announces receipt of European and Australian approvals of MRI labeling on ReActiv8® Restorative Neurostimulation System™
Related Deal lead
Cedric MoreauRelated Deal lead
Antoine PapiernikRelated Strategy
CrossoverRelated Strategy
CapitalRelated Company
Mainstay MedicalDublin, Ireland – 9 July 2024 – Mainstay Medical Holdings plc today announced that it has received regulatory approvals in the European Union, the United Kingdom and Australia for full-body MR conditional labeling for the ReActiv8® Restorative Neurostimulation system. As a result, all current and future ReActiv8 patients in Europe and Australia implanted with the commercially available 45 cm leads have the ability to undergo 1.5T full-body scans. Specific scan conditions and safety information are provided in the ReActiv8 MRI Guidelines manuals for each territory.
The MRI approvals were achieved in connection with Mainstay receiving certificates issued by its Notified Body confirming conformity with the Medical Device Regulations (MDR) of both the European Union and the United Kingdom.
“These MRI approvals will allow us to significantly broaden access to ReActiv8 for patients in Europe and Australia who may require (or develop the need for) MRI imaging post-implantation, complementing our earlier approval of MRI labeling in the United States,” stated Jason Hannon, Chief Executive Officer of Mainstay Medical. “In addition, we are proud of our continued commitment to patient safety and product quality, as shown by our being among the first in the neuromodulation field to achieve MDR certification for Europe and the UK.”
Customer information emails will be sent, and MRI Guidelines and related information will be available, next week.
Related News
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Bioptimus Strengthens Commercial and Scientific Leadership with Key Hires
Pi-Cardia’s ShortCut™ becomes First Leaflet Modification Technology to receive CMS NTAP for Valve-in-Valve TAVR
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Nuage Therapeutics welcomes Olivier Corminboeuf and Blandine Guimet to Leadership Team